Ryan Scott

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and death risk by 37%.

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak study results.

A new combination therapy involving sonrotoclax and dexamethasone demonstrated safety, antitumor activity, and early responses in heavily pretreated patients with relapsed/refractory multiple myeloma harboring t(11:14).

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease control.

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.

The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.

A study showed that a treatment regimen called BOVen was safe and effective in producing responses in older patients with mantle cell lymphoma.

A promising new treatment option has emerged for patients with a specific type of gastrointestinal stromal tumor that has become resistant to standard therapy.

The IMROZ trial reveals significant improvements in PFS for patients with newly diagnosed, transplant-ineligible multiple myeloma.

With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer.

In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.

When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.

Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.

Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.

In an exploratory analysis, different doses of fam-trastuzumab deruxtecan-nxki revealed consistent intracranial responses in HER2-mutated non–small cell lung cancer with treated or untreated brain metastases at baseline.

A novel CD20xCD3 bispecific antibody showed promising safety and preliminary antitumor activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

In the phase 2 DESTINY-PanTumor01 trial, trastuzumab deruxtecan showed clinically meaningful pan-tumor activity in patients with a range of solid tumors harboring HER2 mutations.

NXC-201 has demonstrated safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

At a median follow-up of 4.1 months, the overall response rate across all patients with advanced solid tumors treated with BL-B01D1 was 45.3%, according to data from a phase 1 study.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Adding CTX-009 to paclitaxel generated promising responses for patients with advanced biliary tract cancer when given in the second- and third-line settings.

Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Poorer outcomes were shown in Black patients with hormone receptor-positive breast cancer, including in patients with similar 21-gene recurrence scores.

Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.

Sacituzumab govitecan-hziy vs single-agent docetaxel with be evaluated in the phase 3 EVOKE-01 trial of patients with metastatic non–small cell lung cancer.